1
|
Hanafi B, Beauchet A, Di Lernia V, Lasek A, Severino-Freire M, Barbarot S, Hadj-Rabia S, Phan A, Bursztejn AC, Maruani A, Chaby G, Quiles-Tsimaratos N, Phan C, Zitouni J, Mazereeuw-Hautier J, Mahé E. Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real-life data from the BiPe cohorts. Pediatr Dermatol 2023; 40:835-840. [PMID: 37442765 DOI: 10.1111/pde.15393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Accepted: 06/25/2023] [Indexed: 07/15/2023]
Abstract
BACKGROUND Palmoplantar plaque psoriasis is a frequent clinical subtype of childhood psoriasis. This study evaluated the effectiveness of biologic therapies in children with palmoplantar plaque psoriasis using data from the two Biological treatments for Pediatric Psoriasis (BiPe) cohorts. METHODS Data for all 170 patients included in the BiPe cohorts were analyzed. Data on the effectiveness (PGA, PASI between baseline and 3 months of treatment) of biologic therapies were then compared between children with palmoplantar plaque psoriasis (n = 20) and those with generalized plaque psoriasis (n = 136). Clinical and demographic data were also analyzed. RESULTS Children in the palmoplantar group were more likely to be male (p = .04), with an earlier age of psoriasis onset (p < .001), and more frequent nail involvement (p < .001). After 3 months of biologic treatment, mean PGA scores were higher in the palmoplantar group than in the generalized plaque psoriasis group (p = .004). In the palmoplantar group, continuation rates were higher for adalimumab than for etanercept or ustekinumab (p = .01). Primary inefficacy was a more frequent reason for stopping biologic therapies in the palmoplantar group (p = .01), and disease remission was less frequent (p = .05). Combined systemic and biologic therapies were more frequently used in palmoplantar plaque psoriasis (p < .001). CONCLUSIONS This study demonstrated the treatment-resistant nature of palmoplantar plaque psoriasis and indicated that adalimumab could be the most effective biologic treatment. Larger studies are needed to allow therapeutic algorithms for palmoplantar plaque psoriasis to be proposed in pediatric psoriasis management guidelines.
Collapse
Affiliation(s)
- Bochra Hanafi
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
| | - Alain Beauchet
- Department of Public Health, Hôpital Raymond Poincaré, Garches, France
| | - Vito Di Lernia
- Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy
| | - Audrey Lasek
- Dermatology Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Maëlla Severino-Freire
- Dermatology Department, Centre de référence des maladies rares de la peau et des muqueuses, Hôpital Larrey, Toulouse, France
| | - Sébastien Barbarot
- Dermatology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Smail Hadj-Rabia
- Dermatology Department, INSERM U1163 & Institut Imagine, Centre Hospitalier Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes-Sorbonne, Paris Cité, Paris, France
| | - Alice Phan
- Paediatric Department, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
| | - Anne-Claire Bursztejn
- Dermatology Department, Hôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - Annabel Maruani
- Unit of Pediatric Dermatology, Department of Dermatology, University of Tours and Nantes, INSERM 1246 SPHERE-CHRU Tours, Tours, France
| | | | | | - Céline Phan
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
| | - Jinane Zitouni
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
| | - Juliette Mazereeuw-Hautier
- Dermatology Department, Centre de référence des maladies rares de la peau et des muqueuses, Hôpital Larrey, Toulouse, France
| | - Emmanuel Mahé
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
| |
Collapse
|
2
|
Vanlerberghe J, Dezoteux F, Martin C, Jachiet M, Soria A, Tétart F, Modeste-Duval AB, Bursztejn AC, Misery L, Aubin F, Lasek A, Leleu C, Du-Thanh A, Pasteur J, Pralong P, Nosbaum A, Droitcourt C, Viguier M, Tauber M, Seneschal J, Barbarot S, Staumont-Sallé D. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2023; 88:900-904. [PMID: 36280001 DOI: 10.1016/j.jaad.2022.10.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 10/11/2022] [Accepted: 10/14/2022] [Indexed: 11/09/2022]
Affiliation(s)
- Julia Vanlerberghe
- CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France
| | - Frédéric Dezoteux
- CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France
| | - Claire Martin
- Department of Biostatistics, CHU Lille, Lille, France
| | - Marie Jachiet
- Université de Paris, Faculté de Médecine, AP-HP, Service de Dermatologie, Hôpital Saint-Louis, Paris, France
| | - Angèle Soria
- Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France, Sorbonne Universités Paris, Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France
| | - Florence Tétart
- Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France
| | | | | | - Laurent Misery
- Department of Dermatology, University Hospital of Brest, Brest, France
| | - François Aubin
- Service de Dermatologie, Inserm 1098, Centre Hospitalier Régional Universitaire de Besançon, Université de Franche Comté, Besançon, France
| | - Audrey Lasek
- Service de Dermatologie, Hôpital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France
| | - Camille Leleu
- Service de Dermatologie, Hôpital Le Bocage, CHU Dijon, Dijon, France
| | - Aurélie Du-Thanh
- Service de Dermatologie, CHU Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier, France
| | - Justine Pasteur
- Dermatology Department, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - Pauline Pralong
- Dermatology and Allergology Department, Grenoble University Hospital, Grenoble, France
| | - Audrey Nosbaum
- Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, University of Lyon, CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Catherine Droitcourt
- Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, UMR_S 1085, Irset (Institut de recherche en santé, environnement et travail), EHESP, Inserm, Université de Rennes, Rennes, France
| | - Manuelle Viguier
- Department of Dermatology, Hôpital Robert Debré, Université de Reims Champagne-Ardenne and EA 7509 (IRMAIC), Reims, France
| | - Marie Tauber
- Dermatology Department, Toulouse University Hospital and Inserm UMR 1291- CNRS, Infinity (L'Institut Toulousain des Maladies Infectieuses et Inflammatoires), Toulouse, France
| | - Julien Seneschal
- Service de Dermatologie, Centre de Référence des Maladies Rares de la Peau, CNRS UMR 5164, ImmunoConCept, Université de Bordeaux, Hôpital Saint André, CHU de Bordeaux, Bordeaux, France
| | - Sébastien Barbarot
- Nantes Université, Department of Dermatology, CHU Nantes, UMR 1280 PhAN, INRAE, Nantes, France
| | - Delphine Staumont-Sallé
- CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France.
| |
Collapse
|
3
|
Zitouni J, Bursztejn A, Belloni Fortina A, Beauchet A, Di Lernia V, Lesiak A, Thomas J, Topkarci Z, Murashkin N, Brzezinski P, Torres T, Chiriac A, Luca C, Mcpherson T, Akinde M, Maruani A, Epishev R, Vidaurri De La Cruz H, Luna P, Amy De La Breteque M, Lasek A, Bourrat E, Bachelerie M, Mallet S, Steff M, Bellissen A, Neri I, Zafiriou E, Van Den Reek J, Sonkoly E, Kupfer-Bessaguet I, Leducq S, Mahil S, Smith C, Flohr C, Bachelez H, Mahé E. COVID-19 et psoriasis de l’enfant : facteurs associés à une évolution défavorable de la COVID-19 et impact de l’infection sur le psoriasis. Registre Chi-PsoCov. Annales de Dermatologie et de Vénéréologie - FMC 2022. [PMCID: PMC9748132 DOI: 10.1016/j.fander.2022.09.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
4
|
Lasek A, Bellon N, Mallet S, Puzenat E, Bursztejn AC, Abasq C, Mazereeuw-Hautier J, Chiaverini C, Hubiche T, Raison Peyron N, Du Thanh A, Barbarot S, Aubert H, Reguiai Z, Droitcourt C, Fievet C, Bellissen A, Bachelerie M, Nosbaum A, Leymarie A, Armingaud P, Masson Regnault M, Mahé E. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicenter retrospective cohort in daily practice. J Eur Acad Dermatol Venereol 2022; 36:2423-2429. [PMID: 35854650 DOI: 10.1111/jdv.18450] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 06/24/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD). OBJECTIVE The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice. METHODS Patients aged 6 to 11, who had received a first dose of dupilumab were included in this multicenter retrospective cohort study. The primary endpoint was change in SCORAD after 3 months of treatment. Secondary endpoints were change in IGA score at 3 months, proportion of patients with SCORAD50 and SCORAD75, description of adverse events and proportion of children in our cohort who would be excluded from pivotal phase 3 clinical trial. RESULTS 80 patients were included. After 3 months of treatment, there was a significant decrease in SCORAD (mean: 21.8 ± 13.8 vs 53.9 ± 18.5; p<0.0001) and IGA (1.3 ± 0.8 vs 3.5 ± 0.7; p<0.0001). Conjunctivitis was observed in 11.3%(n=9/80); 3 patients experienced dupilumab facial redness (DFR); 17.5% (n=14/80) reported injection site reactions; 6.3% (n=5/80) discontinued treatment. 61.2 % (n=49/80) children were ineligible in the phase 3 trial. LIMITATIONS There is no control group. Because it was a real life study based on information from patient medical records in a French multicenter cohort, we cannot rule out the presence of reporting bias generated by the use of patient reported characteristics and missing information. CONCLUSION These real-life data confirm the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo but it also revealed a lower frequency of DFR and conjunctivitis. However, administration in injectable form may be a barrier in this age group.
Collapse
Affiliation(s)
- A Lasek
- Department of dermatology, Hôpital Saint Vincent de Paul, GHICL, Lille, France
| | - N Bellon
- Department of dermatology, Centre Hospitalier Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - S Mallet
- Department of dermatology, venereology, and cancerology, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - E Puzenat
- Department of dermatology, Centre Hospitalier Universitaire deBesançon, Besançon, France
| | - A C Bursztejn
- Department of dermatology, Hôpitaux de Brabois, CHRU Nancy, Vandœuvre-Lès-, Nancy, France
| | - C Abasq
- Department of dermatology, Centre Hospitalier Universitaire de Brest, Brest, France
| | - J Mazereeuw-Hautier
- Department of dermatology, Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier Toulouse, France
| | - C Chiaverini
- Department of dermatology, hospital Archet 2, ESPIC CHU-Lenval, Nice, France
| | - T Hubiche
- Department of dermatology, hospital Archet 2, ESPIC CHU-Lenval, Nice, France
| | - N Raison Peyron
- Department of dermatology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - A Du Thanh
- Department of dermatology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - S Barbarot
- Department of dermatology, Hôtel-Dieu, Nantes, France
| | - H Aubert
- Department of dermatology, Hôtel-Dieu, Nantes, France
| | - Z Reguiai
- Department of dermatology, Polyclinique de Courlancy, Reims, France
| | - C Droitcourt
- Department of dermatology, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France
| | - C Fievet
- Department of dermatology, Centre Hospitalier Régional Universitaire Lille, Lille, France
| | - A Bellissen
- Department of dermatology, Centre Hospitalier d'Aubagne, Aubagne, France
| | - M Bachelerie
- Department of dermatology, Centre Hospitalier Universitaire de Clermond Ferrand, Clermont-Ferrand, France
| | - A Nosbaum
- Department of Clinical Immunology and Allergy, Lyon-Sud University Hospital, Pierre Bénite, Lyon, Lyon, France
| | - A Leymarie
- Department of dermatology, Centre Hospitalier Universitaire de Caen, Caen, France
| | - P Armingaud
- Department of dermatology, Centre Hospitalier d'Orléans, Orléans, France
| | | | - E Mahé
- Department of dermatology, Centre Hospitalier Victor Dupouy, Argenteuil, France
| | | | | |
Collapse
|
5
|
Zitouni J, Bursztejn A, Belloni Fortina A, Beauchet A, Di Lernia V, Lesiak A, Thomas J, Topkarci Z, Murashkin N, Brzezinski P, Torres T, Chiriac A, Luca C, McPherson T, Akinde M, Maruani A, Epishev R, Vidaurri de la Cruz H, Luna P, Amy de la Bretêque M, Lasek A, Bourrat E, Bachelerie M, Mallet S, Steff M, Bellissen A, Neri I, Zafiriou E, van den Reek J, Sonkoly E, Mahil S, Smith C, Flohr C, Bachelez H, Mahé E. Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). J Eur Acad Dermatol Venereol 2022; 36:2076-2086. [PMID: 35748102 PMCID: PMC9349726 DOI: 10.1111/jdv.18361] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 06/10/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. OBJECTIVES The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. METHODS We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. RESULTS One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). DISCUSSION Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.
Collapse
Affiliation(s)
- J. Zitouni
- Department of DermatologyHôpital Victor DupouyArgenteuilFrance
| | - A.‐C. Bursztejn
- Department of DermatologyHôpitaux de Brabois, Centre Hospitalier Universitaire de NancyVandœuvre‐lès‐NancyFrance
| | - A. Belloni Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMEDUniversity of PadovaPadovaItaly
| | - A. Beauchet
- Department of Public HealthHôpital Ambroise ParéBoulogne‐BillancourtFrance
| | - V. Di Lernia
- Dermatology UnitArcispedale S. Maria Nuova, Azienda USL‐IRCCS di Reggio EmiliaReggio EmiliaItaly
| | - A. Lesiak
- Department of Dermatology, Peadiatric Dermatology and OncologyMedical Univeristy of LodzLodzPoland
| | - J. Thomas
- J. T. Skin Care CentreChennaiTamil NaduIndia
| | - Z. Topkarci
- Department of DermatologyDr. Sadi Konuk Training and Research HospitalIstanbulTurkey
| | - N. Murashkin
- Department of DermatologyFederal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian FederationMoscowRussia
| | - P. Brzezinski
- Department of DermatologyVoivodship Specialist Hospital in SlupskUstkaPoland
| | - T. Torres
- Department of DermatologyCentro Hospitalar Universitário do PortoPortoPortugal
| | - A. Chiriac
- Department of Dermatology, Nicolina Medical CenterP. Poni Institute of Macromolecular Chemistry, Romanian AcademyIașiRomania
| | - C. Luca
- Infectious Disease Department, “Sf. Parascheva” Clinical Hospital“Gr. T. Popa” University of MedicineIasiRomania
| | - T. McPherson
- Department of DermatologyOxford University Hospitals NHS TrustOxfordUK
| | - M. Akinde
- Department of Paediatric Dermatology, St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation TrustLondonUK
| | - A. Maruani
- Unit of Pediatric Dermatology, Department of DermatologyUniversity of Tours and Nantes, INSERM 1246 SPHERE ‐ CHRU ToursToursFrance
| | - R. Epishev
- Department of DermatologyFederal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian FederationMoscowRussia
| | - H. Vidaurri de la Cruz
- Servicio de Dermatología PediátricaHospital General de México Dr. Eduardo Liceaga, Secretaría de SaludCiudad de MéxicoMexico
| | - P.C. Luna
- Department of DermatologyHospital AlemánCiudad Autónoma de Buenos AiresArgentina
| | | | - A. Lasek
- Department of Dermatology, Hôpital Saint Vincent de PaulUniversité Catholique de LilleLilleFrance
| | - E. Bourrat
- Department of DermatologyHôpital Robert Debré, AP‐HPParisFrance
| | - M. Bachelerie
- Department of DermatologyCentre Hospitalier UniversitaireClermont‐FerrandFrance
| | - S. Mallet
- Department of Dermatology, Hôpital de la TimoneAssistance‐publique‐Hôpitaux de MarseilleMarseilleFrance
| | - M. Steff
- Department of DermatologyCentre Hospitalier Intercommunal Robert BallangerAulnay‐sous‐BoisFrance
| | - A. Bellissen
- Department of DermatologyCentre Hospitalier Edmond GarcinAubagneFrance
| | - I. Neri
- Department of DermatologyIRCSS Azienda Ospedaliero Universitaria di BolognaBolognaItaly
| | - E. Zafiriou
- Department of Dermatology, Faculty of Medicine, School of Health SciencesUniversity of ThessalyLarissaGreece
| | | | - E. Sonkoly
- Dermatology and Venereology Division, Department of Medicine SolnaKarolinska InstitutetStockholmSweden,Center for Molecular Medicine (CMM)Karolinska InstitutetStockholmSweden,Dermatology, Department of Medical SciencesUppsala UniversityUppsalaSweden
| | - S.K. Mahil
- St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation Trust and King's College LondonLondonUK
| | - C.H. Smith
- St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation Trust and King's College LondonLondonUK
| | - C. Flohr
- Department of Paediatric Dermatology, St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation TrustLondonUK
| | - H. Bachelez
- Department of DermatologyHôpital Saint‐Louis, AP‐HPParisFrance,Laboratory of Genetic Skin Diseases, INSERM U1163, Imagine InstituteUniversité de ParisParisFrance
| | - E. Mahé
- Department of DermatologyHôpital Victor DupouyArgenteuilFrance
| | | |
Collapse
|
6
|
Zitouni J, Beauchet A, Curmin R, Di Lernia V, Bursztejn AC, Mazereeuw-Hautier J, Gottlieb J, Lasek A, Aubert H, Droitcourt C, Bulai-Livideanu C, Fortina AB, Caroppo F, Quiles-Tsimaratos N, Mallet S, Barthélémy H, Puzenat E, Bouilly-Auvray D, Neri I, Phan C, Mahé E. Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr). Paediatr Drugs 2022; 24:281-292. [PMID: 35397731 DOI: 10.1007/s40272-022-00501-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/13/2022] [Indexed: 12/19/2022]
Abstract
INTRODUCTION Biological therapies are valuable treatments for severe psoriasis. Children aged under 12 years are underrepresented in therapeutic trials for these drugs. The objective of the 'BiPe Jr' cohort study was to evaluate the drug survival, effectiveness, tolerance and switching patterns of biological therapies in children under 12 years of age with psoriasis. METHODS We conducted a multicentre retrospective study of children with psoriasis who received at least one injection of a biological agent, even off-licence, before the age of 12 years in France and Italy, collecting the data between April and August 2021. The data collected were from March 2012 up to August 2021. RESULTS In total, 82 children (mean age: 9.1 years; females: 61.0%) received 106 treatments. The drugs administered were adalimumab (n = 49), etanercept (n = 37), ustekinumab (n = 15), anakinra (n = 2), infliximab (n = 2) and secukinumab (n = 1). The most common form of psoriasis was plaque psoriasis (62.9%). The Physician Global Assessment and the Psoriasis Area Severity Index (PASI) scores decreased significantly from baseline to 3 months after treatment initiation for the three main biological drugs; PASI went from 14.1 ± 9.4 to 4.1 ± 11.3 for adalimumab (p = 0.001), 14.9 ± 9.3 to 5.1 ± 4.0 for etanercept (p = 0.002) and 11.6 ± 8.3 to 2.6 ± 2.2 for ustekinumab (p = 0.007). A trend towards higher 2-year maintenance rates was observed for ustekinumab and adalimumab, compared with etanercept (p = 0.06). 52 children discontinued their biological therapy, most frequently due to inefficacy (n = 28) and remission (n = 14). Seven serious adverse events (SAEs) were reported, including four severe infections. DISCUSSION Our analyses of drug survival and treatment patterns, combined with those of previous studies conducted in older children, indicate that there is a trend towards higher 2-year survival rates of ustekinumab and adalimumab. The SAEs identified were rare, but highlight the need for increased vigilance concerning infections. Overall, the biological therapies showed good effectiveness and safety profiles when used in daily practice for the treatment of young children with psoriasis.
Collapse
Affiliation(s)
- Jinane Zitouni
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
| | - Alain Beauchet
- Public Health Department, Centre Hospitalier Universitaire Ambroise Paré, Boulogne-Billancourt, France
| | - Raphaëlle Curmin
- Sorbonne University, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Vito Di Lernia
- Dermatology unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy
| | - Anne-Claire Bursztejn
- Dermatology Department, Hôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Vandoeuvre-lès-Nancy, France
| | - Juliette Mazereeuw-Hautier
- Dermatology Department, Centre de référence des maladies rares de la peau et des muqueuses, Hôpital Larrey, Toulouse, France
| | - Jérémy Gottlieb
- Immunology and Dermatology Department, Hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin Bicêtre, France
| | - Audrey Lasek
- Dermatology Department,, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Hélène Aubert
- Dermatology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Catherine Droitcourt
- Dermatology Department, Centre Hospitalier Universitaire Pontchaillou, Rennes, France
| | | | - Anna Belloni Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padua, Italy
| | - Francesca Caroppo
- Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padua, Italy
| | | | - Stéphanie Mallet
- Dermatology Department, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - Hugues Barthélémy
- Dermatology Department, Centre Hospitalier d'Auxerre, Auxerre, France
| | - Eve Puzenat
- Dermatology Department, Centre Hospitalier Universitaire Saint-Jacques, Besançon, France
| | | | - Iria Neri
- Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Céline Phan
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
| | - Emmanuel Mahé
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France.
| | | |
Collapse
|
7
|
Mahe E, Shourick J, Mallet S, Abasq C, Bursztejn AC, Sampogna F, Bodemer C, Boralevi F, Barbarot S, Lasek A, Merhand S, Taïeb C, Ezzedine K. Perceived clinical severity of atopic dermatitis in children: comparison between patients' and parents' evaluation. J Eur Acad Dermatol Venereol 2022; 36:e592-e594. [PMID: 35293021 DOI: 10.1111/jdv.18083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 02/14/2022] [Accepted: 02/24/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Emmanuel Mahe
- Department of Dermatology, Hôpital Victor Dupouy, 69 rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France
| | - Jason Shourick
- Dermatologist, Epidemiologist, Hôpital de Toulouse, Toulouse, France
| | - Stephanie Mallet
- Service de Dermatologie, Vénéréologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - Claire Abasq
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| | - Anne-Claire Bursztejn
- Service de Dermatologie, CHU de Nancy-Hôpitaux de Brabois, Rue du Morvan, 54500, Vandœuvre-lès-Nancy, France
| | - Francesca Sampogna
- Health Services Research Unit, Istituto Dermopatico dell'Immacolata, Rome, Italy
| | | | - Franck Boralevi
- Pediatric Dermatology Unit, Hospital Pellegrin, University Centre Hospital of Bordeaux, Bordeaux, France
| | - Sébastien Barbarot
- Department of Dermatology, Nantes University Hospital, 44035, Nantes, France
| | - Audrey Lasek
- Service de dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, France
| | | | - Charles Taïeb
- Patients Priority Department, European Market Maintenance Assessment [EMMA], Fontenay Sous Bois, France
| | - Khaled Ezzedine
- Department of Dermatology, Hôpital Henri Mondor, FR-94000, Creteil, France
| |
Collapse
|
8
|
Phan C, Beauchet A, Reguiai Z, Severino-Freire M, Mazereeuw-Hautier J, Bursztejn AC, Barbarot S, Hadj-Rabia S, Girard C, Phan A, Lacour JP, Lasek A, Abasq C, Brenaut E, Perrussel M, Droitcourt C, Mallet S, Piram M, Fougerousse AC, Barthélémy H, Balguérie X, Mahé E. Switching biologics in children with psoriasis: Results from the BiPe cohort. Pediatr Dermatol 2022; 39:35-41. [PMID: 34888920 DOI: 10.1111/pde.14845] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 09/28/2021] [Accepted: 10/09/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND There is currently little information on switching biologics in pediatric psoriasis. OBJECTIVE To evaluate the real-world clinical practice and safety of switching biologics in the "Biological Treatments for Pediatric Psoriasis" (BiPe) cohort. METHODS Data for all 134 patients included in the BiPe cohort were analyzed. A further evaluation of the subpopulation of patients who switched from a first-line biologic to a second-line biologic was then conducted. Drug survival rates were also compared between biologics given as first-line or second-line agents. RESULTS Overall, 29 patients (female: 55%; mean age: 16.6 ± 3.0 years) switched between two biologics. Etanercept (ETN) was the first-line biologic used in 23 patients: 16 (69.6%) switched to adalimumab (ADA) and seven (30.4%) to ustekinumab (UST). Six patients received first-line ADA and switched to UST. Loss of efficacy (62.1%), primary inefficacy (20.7%), and parental choice (6.9%) were the main reasons for switching biologics. One (3.4%) of the switches was performed because of adverse events or intolerance. For UST and ADA, the 18-month drug survival rate did not differ according to whether the agent was given as a first-line or second-line biologic (UST: P = .24; ADA: P = .68). No significant differences in drug survival rates were observed between the three different switches (ADA to UST, ETN to ADA, and ETN to UST). CONCLUSION Our study provided key insights into the real-life clinical practice of switching biologics in pediatric psoriasis patients. However, more information and guidance on switching biologics in pediatric psoriasis are needed to improve real-life practice and outcomes.
Collapse
Affiliation(s)
- Céline Phan
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - Alain Beauchet
- Service de Santé Publique, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Ziad Reguiai
- Service de Dermatologie, Polyclinique Courlancy, Hôpital Robert Debré, Reims, France
| | | | | | | | | | - Smaïl Hadj-Rabia
- Service de Dermatologie, INSERM U1163 & Institut Imagine, Centre Hospitalier Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne, Paris, France
| | - Céline Girard
- Service de Dermatologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Alice Phan
- Service de Pédiatrie, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
| | | | - Audrey Lasek
- Service de Dermatologie, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Claire Abasq
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| | - Emilie Brenaut
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| | - Marc Perrussel
- Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France
| | - Catherine Droitcourt
- Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France
| | - Stéphanie Mallet
- Service de Dermatologie, Vénéréologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - Maryam Piram
- Service de Dermatologie, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin Bicêtre, France
| | | | | | - Xavier Balguérie
- Service de Dermatologie, Centre Hospitalier Universitaire Charles-Nicolle, Rouen, France
| | - Emmanuel Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | | |
Collapse
|
9
|
Zitouni J, Fortina AB, Bursztejn AC, Beauchet A, Lesiak A, Murashkin N, Maruani A, Di Lernia V, Lasek A, Amy de la Breteque M, Torres T, Epishev R, Bourrat E, Bachelez H, Mahé E. COVID-19 et psoriasis chez l’enfant. Données d’une cohorte internationale. Annales de Dermatologie et de Vénéréologie - FMC 2021. [PMCID: PMC8603670 DOI: 10.1016/j.fander.2021.09.439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Introduction Le psoriasis touche 0,5 à 1 % des enfants. L’infection à SARS-CoV-2 pourrait avoir un impact sur le psoriasis (poussées induites voire psoriasis de novo), et les traitements systémiques du psoriasis pourraient favoriser la survenue de formes plus sévères de COVID-19. Chez l’adulte psoriasique la COVID-19 est plus sévère chez les patients âgés, obèses, « non blancs » et sous immunosuppresseurs non biologiques (registre PsoProTect). Il n’existe pas de données pédiatriques. L’objectif de l’étude menée chez des enfants psoriasiques ayant contracté l’infection par le SARS-CoV-2 était de :. – étudier l’impact de l’infection à SARS-CoV2 sur le psoriasis (poussée de psoriasis, changement de phénotype, psoriasis de novo) ; – et étudier l’impact des traitements systémiques, biologiques ou non, sur le risque de développer une forme sévère de COVID-19. Matériel et méthodes Étude transversale, multicentrique, internationale, menée à partir de février 2021, par appel à cas auprès de la SFDP, du GrPso et de la SIDerP (Italie), et relayé par la BSPD (Royaume-Uni) et l’ESPD (Europe). Tout enfant (< 18 ans) psoriasique présentant une infection à SARS-CoV-2 symptomatique ou non était inclus. Le psoriasis pouvait préexister à l’infection ou se développer dans le mois suivant l’infection à SARS-CoV-2 (psoriasis de novo). Résultats Un total de 46 enfants (France, n = 30 ; Italie, n = 3 ; Pologne, n = 9 ; Russie, n = 3 ; et Portugal, n = 1) ont été inclus. L’âge moyen était de 12,2 ± 4,0 ans ; il y avait 20 (43,5%) filles. Les caractéristiques du psoriasis sont détaillées dans le tableau. Quatorze enfants étaient sous biothérapies et 5 sous systémiques oraux. Dans 84,8 % des cas l’infection à SARS-CoV-2 était confirmée. Dans 63 % des cas, il s’agissait de formes symptomatiques, avec en cas de symptômes une durée moyenne des symptômes de 6,4 ± 5,2 j. Le traitement systémique a été maintenu dans 84,2 % des cas. Dans 5 cas le psoriasis s’était aggravé au décours de la COVID-19 avec un phénotype similaire, dans 1 cas il s’agissait d’un psoriasis de novo. Les enfants sous biothérapies ne présentaient pas de formes plus sévères, avec même une tendance, en cas de forme symptomatique, à une durée plus courte des symptômes (4,0 vs 7,5 j, p = 0,047) par rapport aux enfants sans traitements. Discussion Ce 1er travail mené chez l’enfant psoriasique infecté par le SARS-CoV-2 montre que l’infection peut induire dans près de 13 % des cas des poussées de psoriasis, voire un psoriasis de novo. En cas de forme symptomatique, il s’agissait toujours de formes bénignes, et les biothérapies semblaient plutôt associées à une forme moins sévère de COVID-19, confirmant ainsi les données observées chez l’adulte (PsoProTect). Malgré la faiblesse de l’effectif, et en s’appuyant sur les données adultes, nous pouvons rassurer les enfants psoriasis recevant des systémiques, notamment des biothérapies, en cas d’infection par le SARS-CoV-2.
Collapse
|
10
|
Bursztejn AC, Shourick J, Bodemer C, Lasek A, Mahé E, Merhand S, Sampogna F, Taïeb C, Boralevi F, Ezzedine K, Barbarot S, Mallet S, Abasq C. Feelings of guilt in parents of children with atopic dermatitis. J Eur Acad Dermatol Venereol 2021; 36:e155-e157. [PMID: 34586676 DOI: 10.1111/jdv.17712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 09/17/2021] [Indexed: 11/30/2022]
Affiliation(s)
- A C Bursztejn
- Service de Dermatologie, CHU de Nancy-Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France
| | - J Shourick
- Dermatologist, Epidemiologist, Hôpital de Toulouse, Toulouse, France
| | - C Bodemer
- Department of Dermatology, Hôpital Necker, AP-HP, Paris, France
| | - A Lasek
- Service de dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France
| | - E Mahé
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | - S Merhand
- French Eczema Association, Redon, France
| | - F Sampogna
- Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy
| | - C Taïeb
- Patients Priority Department, European Market Maintenance Assessment [EMMA], Fontenay Sous Bois, France
| | - F Boralevi
- Pediatric Dermatology Unit, Hospital Pellegrin, University Centre Hospital of Bordeaux, Bordeaux, France
| | - K Ezzedine
- Department of Dermatology, Hôpital Henri Mondor, Creteil, France
| | - S Barbarot
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - S Mallet
- Service de Dermatologie, Vénéréologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - C Abasq
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| |
Collapse
|
11
|
Barbarot S, Boralevi F, Shourick J, Sampogna F, Mahé E, Merhand S, Bursztejn AC, Mallet S, Ezzedine K, Abasq C, Taïeb C, Lasek A, Bodemer C. Characteristics of children and adolescents with atopic dermatitis who attended therapeutic patient education. J Eur Acad Dermatol Venereol 2021; 35:2263-2269. [PMID: 34273203 DOI: 10.1111/jdv.17526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 06/25/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease. Therapeutic patient education (TPE) has been demonstrated to be effective in AD in reducing disease severity and improving coping and quality of life. OBJECTIVES To describe the sociodemographic and clinical characteristics of children and adolescents with AD who had attended TPE sessions, as well as the characteristics of their parents, and compare them with those who did not attend TPE. METHODS Parents of children with AD aged 6-17 years old were recruited from a representative sample of the French population contacted by e-mail. Sociodemographic data and clinical information were collected in patients and parents. Clinical severity was assessed by parents using a proxy version of the Patient-Oriented Eczema Measure (POEM). Attendance to TPE sessions was assessed by the following question 'did your child or one or both parents attended TPE for AD?'. Also, the number of sessions was recorded. Determinants of TPE attendance were evaluated by univariable and multivariable analyses. RESULTS Data were collected on 1063 parents and children with AD. A total of 131 (12.3%) children and/or parents attended TPE sessions. Most of them attended 2-5 TPE sessions. In that group, there were 85 boys (64.9%), and severity evaluated by POEM was mild in 29.8%, moderate in 52.7% and severe in 17.6% of patients. In the multivariable model, attending TPE sessions was significantly associated with sex of the child (boy vs. girl), consultation with a dermatologist or a paediatrician, high clinical severity and presence of AD in parents. CONCLUSIONS Despite recommendations, the use of TPE in children with AD is still low in France. There is a need for implementing such programmes in the management of the disease, in particular when the disease is severe.
Collapse
Affiliation(s)
- S Barbarot
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - F Boralevi
- Pediatric Dermatology Unit, Hospital Pellegrin, University Centre Hospital of Bordeaux, Bordeaux, France
| | - J Shourick
- Dermatologist, Epidemiologist, Hôpital de Toulouse, Toulouse, France
| | - F Sampogna
- Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy
| | - E Mahé
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | - S Merhand
- French Eczema Association, Association Fraçaise de l'Eczéma, Redon, France
| | - A-C Bursztejn
- Service de Dermatologie, CHU de Nancy-Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France
| | - S Mallet
- Service de Dermatologie, Vénéréologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance-publique, Hôpitaux de Marseille, Marseille, France
| | - K Ezzedine
- Department of Dermatology, Hôpital Henri Mondor, Creteil, France
| | - C Abasq
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| | - C Taïeb
- Patients Priority Department, European Market Maintenance Assessment [EMMA], Fontenay Sous Bois, France
| | - A Lasek
- Service de Dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France
| | - C Bodemer
- Department of Dermatology, Hôpital Necker, AP-HP, Paris, France
| |
Collapse
|
12
|
Marcant P, Balayé P, Merhi R, Jendoubi F, Nosbaum A, Raison-Peyron N, Du-Thanh A, Lasek A, Ferrier le Bouedec MC, Tetart F, Valois A, Barbarot S, Soria A, Jachiet M, Staumont-Sallé D. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol 2021; 35:e394-e396. [PMID: 33594731 DOI: 10.1111/jdv.17177] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 02/09/2021] [Indexed: 12/17/2022]
Affiliation(s)
- P Marcant
- Service de Dermatologie CHU Lille, INFINITE U1286 Inserm, Univ. Lille, Lille, France
| | - P Balayé
- Univ. Lille, CHU Lille, ULR 2694 - METRICS : Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France
| | - R Merhi
- Service de Dermatologie, Hôpital Saint André, Centre de Référence des Maladies Rares de la Peau, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - F Jendoubi
- Dermatology and Allergology department, Toulouse University Hospital, Toulouse, France
| | - A Nosbaum
- Allergy and Clinical Immunology Department, Univ Lyon, Lyon Sud University Hospital, Pierre Benite, France
| | - N Raison-Peyron
- Service de Dermatologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - A Du-Thanh
- Service de Dermatologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - A Lasek
- Service de Dermatologie, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | | | - F Tetart
- Service de Dermatologie, Clinique Dermatologique, CHU de Rouen, Rouen, France
| | - A Valois
- Service de dermatologie, Hôpital d'instruction des armées Sainte-Anne, boulevard Sainte-Anne, Toulon, France
| | - S Barbarot
- Department of Dermatology, Nantes Université, CHU Nantes, UMR 1280 PhAN, INRAE, Nantes, France
| | - A Soria
- Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France
| | - M Jachiet
- Dermatology Department, Université́ Paris Diderot Paris VII, Sorbonne Paris Cité APHP, Saint Louis Hospital, Paris, France
| | - D Staumont-Sallé
- Service de Dermatologie CHU Lille, INFINITE U1286 Inserm, Univ. Lille, Lille, France
| | | |
Collapse
|
13
|
Hubiche T, Phan A, Leducq S, Rapp J, Fertitta L, Aubert H, Barbarot S, Chiaverini C, Giraudeau B, Lasek A, Mallet S, Labarelle A, Piram M, McCuaig C, Martin L, Monitor L, Nicol I, Bissuel M, Bellissen A, Jullien D, Lesort C, Vabres P, Maruani A. Acute acral eruptions in children during the COVID-19 pandemic: Characteristics of 103 children and their family clusters. Ann Dermatol Venereol 2021; 148:94-100. [PMID: 33551211 PMCID: PMC7831537 DOI: 10.1016/j.annder.2020.11.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 10/15/2020] [Accepted: 11/26/2020] [Indexed: 12/20/2022]
Abstract
Background A marked increase in frequency of acute acral eruptions (AAE) was observed in children during the COVID-19 pandemic in the spring period. Objectives In this observational multicenter study, based on children with AAE, we aimed to assess the proportion of household members possibly infected by SARS-CoV-2. Methods We collected data from all children observed with AAE, prospectively from April 7, 2020 to June 22, 2020, and retrospectively since February 28, 2020. The primary outcome was the household infection rate, defined as the proportion of family clusters having at least one member with COVID-19 infection other than the child with AAE (“index child”). The definition of a case was based on characteristic clinical signs and a positive PCR or serology. Results The study included 103 children in 10 French departments and in Quebec. The median age was 13 years and the interquartile range [8–15], with a female-to-male ratio of 1/1.15. In children with AAE, all PCR tests were negative (n = 18), and serology was positive in 2/14 (14.3%) cases. We found no significant anomalies in the lab results. A total of 66 of the 103 families (64.1%) of included children had at least one other infected member apart from the index child. The total number of household members was 292, of whom 119 (40.8%) were considered possibly infected by SARS-CoV-2. No index children or households exhibited severe COVID-19. Discussion Among the 103 households included, 64.1% had at least one infected member. Neither children with AAE nor their households showed severe COVID-19.
Collapse
Affiliation(s)
- T Hubiche
- Nice University Hospital, Department of Dermatology, 06000 Nice, France
| | - A Phan
- Lyon University Hospital, Department of Pediatric Dermatology, Hospices Civils de Lyon, 69500 Bron, France
| | - S Leducq
- Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Department of Dermatology, 37044 Tours Cedex 9, France
| | - J Rapp
- Nice University Hospital, Department of Dermatology, 06000 Nice, France
| | - L Fertitta
- AP-HP (Paris Hospitals), Paris-Necker Hospital, Department of Dermatology, 75015 Paris, France
| | - H Aubert
- Nantes University Hospital, Department of Dermatology, 44000 Nantes, France
| | - S Barbarot
- Nantes University Hospital, Department of Dermatology, 44000 Nantes, France
| | - C Chiaverini
- Nice University Hospital, Department of Dermatology, 06000 Nice, France
| | - B Giraudeau
- Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Clinical Investigation Center-INSERM 1415, 37000 Tours, France
| | - A Lasek
- Saint Vincent de Paul Hospital, Université catholique de Lille, 59000 Lille, France
| | - S Mallet
- Marseille University Hospital, Department of Dermatology, 13000 Marseille, France
| | - A Labarelle
- Marseille University Hospital, Department of Dermatology, 13000 Marseille, France
| | - M Piram
- Sainte-Justine University Hospital, Division of Dermatology, Montreal, Quebec, Canada
| | - C McCuaig
- Sainte-Justine University Hospital, Division of Dermatology, Montreal, Quebec, Canada
| | - L Martin
- Angers Hospital University, Department of Dermatology, 49000 Angers, France
| | - L Monitor
- Nancy University Hospital, Department of Dermatology, 54511 Vandœuvre-lès-Nancy, France
| | - I Nicol
- Marseille University Hospital, Department of Dermatology, 13000 Marseille, France
| | - M Bissuel
- Casamance Private Hospital, Department of Pediatrics, 13400 Aubagnes, France
| | - A Bellissen
- Marseille University Hospital, Department of Dermatology, 13000 Marseille, France
| | - D Jullien
- Lyon University Hospital, Department of Dermatology, Hospital Edouard Herriot, 69003 Lyon, France
| | - C Lesort
- Lyon University Hospital, Department of Dermatology, Hospital Edouard Herriot, 69003 Lyon, France
| | - P Vabres
- Dijon University Hospital, Department of Dermatology, 21000 Dijon, France
| | - A Maruani
- Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Department of Dermatology, 37044 Tours Cedex 9, France; Tours University Hospital, Clinical Investigation Center-INSERM 1415, 37000 Tours, France.
| | | |
Collapse
|
14
|
Hubiche T, Phan A, Leducq S, Rapp J, Fertitta L, Aubert H, Barbarot S, Chiaverini C, Giraudeau B, Labarelle A, Mc Craig C, Martin L, Monitor L, Nicol I, Piram M, Bissuel M, Bellissen A, Lasek A, Mallet S, Vabres P, Maruani A. Acrosyndromes aigus pédiatriques au cours de l’épidémie de COVID-19 : étude des caractéristiques de la cellule familiale. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Marcant P, Balayé P, Merhi R, Seneschal J, Tauber M, Jendoubi F, Nosbaum A, Raison-Peyron N, Du-Thanh A, Lasek A, Ferrier le Bouedec MC, Tetart F, Valois A, Lefevre G, Barbarot S, Soria A, Jachiet M, Staumont-Sallé D. Hyperéosinophilie associée au traitement par dupilumab dans la dermatite atopique modérée à sévère : étude rétrospective multicentrique du GREAT. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Cuvelier M, Lasek A, Ngendahayo P, Théate I, Sass U, Roquet-Gravy PP, Bulinckx A. [Transitory apocrine hidrocystomatosis of the scrotum]. Ann Dermatol Venereol 2020; 147:361-365. [PMID: 32164923 DOI: 10.1016/j.annder.2019.09.610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Revised: 05/19/2019] [Accepted: 09/19/2019] [Indexed: 10/24/2022]
Abstract
BACKGROUND Apocrine hidrocystomas are benign cystic tumors that develop from apocrine gland proliferation. In most cases, they are translucent solitary lesions of the face, generally found in the periorbital region, on the scalp or on the neck. More rarely, apocrine hidrocystomas may be multiple and appear on the ears, trunk, shoulders and genital area. They generally appear in adulthood, with only a few pediatric cases being reported, of which three in the genital area, with a solitary case of multiple hidrocystomas of the scrotum, although no cases of spontaneous involution of hidrocystomas have previously been reported. PATIENTS AND METHODS Two boys aged 4 and 6 months were seen in consultation for small sub-millimeter size, subcutaneous, black lesions on the scrotum that appeared in the weeks following birth. Histological examination of these lesions resulted in a diagnosis of apocrine hidrocystoma. The children were seen again a few weeks later and the skin lesions had totally disappeared. We report two cases of multiple apocrine hidrocystomas on the scrotum with spontaneous involution diagnosed in a 4- and a 6-month-old boy. DISCUSSION Apocrine hidrocystomas are rare benign adnexal tumors that develop from apocrine sweat glands. They are considered as cystic proliferations of the apocrine glands rather than simple retention cysts. The main differential diagnosis of the rare cases of multiple apocrine hidrocystomas are eccrine hidrocystomas. The treatment of such lesions is based on surgical excision if they are isolated, daily application of topical atropine 1%, or CO2 laser for multiple apocrine hidrocystomas.
Collapse
Affiliation(s)
- M Cuvelier
- Service de dermatologie, grand hôpital de Charleroi, rue de Villers 1, 6280 Loverval, Belgique.
| | - A Lasek
- Service de dermatologie, hôpital Saint-Vincent-De-Paul, boulevard de Belfort, BP 387, 59000 Lille, France
| | - P Ngendahayo
- Service d'anatomopathologie, institut de pathologie et de génétique, avenue Georges-Lemaître 25, 6041 Charleroi, Belgique
| | - I Théate
- Service d'anatomopathologie, institut de pathologie et de génétique, avenue Georges-Lemaître 25, 6041 Charleroi, Belgique
| | - U Sass
- Service de dermatologie, hôpital Saint-Pierre, rue Haute 322, 1000 Bruxelles, Belgique
| | - P-P Roquet-Gravy
- Service de dermatologie, grand hôpital de Charleroi, rue de Villers 1, 6280 Loverval, Belgique
| | - A Bulinckx
- Service de dermatologie, grand hôpital de Charleroi, rue de Villers 1, 6280 Loverval, Belgique
| |
Collapse
|
17
|
Phan C, Beauchet A, Burztejn A, Severino-Freire M, Mazereeuw-Hautier J, Barbarot S, Girard C, Lasek A, Reguiai Z, Sassolas B, Droitcourt C, Perrussel M, Hadj-Rabia S, Mallet S, Phan A, Lacour JP, Bourrat E, Aubin F, Mahé E. Enfants atteints de psoriasis issus de la cohorte BIPE : évaluation de l’éligibilité des enfants traités par biothérapie dans la vie courante pour des études cliniques de phase III. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Mazaud C, Staumont D, Beauchet A, Catteau B, Lasek A, Puzenat E, Aubin F, Barbarot S, Aubert H, Mallet S, Seneschal J, Bessis D, Tauber M, Delaunay J, Droitcourt C, Abasq C, Jachiet M, Nosbaum A, Mahé E. Dupilumab dans la dermatite atopique modérée à sévère de l’enfant. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Affiliation(s)
- Dario Ahangari
- Dermatology Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Manon Gillard
- Dermatology Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Gabriela Certad
- Clinical Research Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Mathieu Bataille
- Dermatology Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Audrey Lasek
- Dermatology Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Phillippe Modiano
- Dermatology Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| |
Collapse
|
20
|
Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC. Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis. Ophthalmol Ther 2019; 8:485-490. [PMID: 31230264 PMCID: PMC6692787 DOI: 10.1007/s40123-019-0191-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Indexed: 12/24/2022] Open
Abstract
We report 10 cases of conjunctivitis in atopic dermatitis (AD) patients treated with dupilumab from November 2017 to November 2018 in our institution, who were referred to the ophthalmology department for diagnosis and management of conjunctivitis. We also describe ocular surface findings in these patients before the first injection of dupilumab. During the first 6 months post initiation of dupilumab, incidence of conjunctivitis was 27% (5/18) in patients treated from November 2017 to April 2018 who had not had ocular examination previously. This rate dropped to 12% (3/25) after systematic ophthalmological referral before initiation of dupilumab. Patients who developed conjunctivitis had mean SCORAD score (Scoring Atopic Dermatitis) of 60.4 ± 20 (35-88) and mean EASI score (Eczema Area and Severity Index) of 37 ± 17 (14.6-56). Mean age was 36 years (20-51). Most patients had a long history of AD (> 10 years). Mean delay of ocular surface inflammation was 3.5 months, ranging from 1 to 8 months. One patient had to discontinue dupilumab because of severe follicular conjunctivitis. We observed two clinical patterns of ocular surface diseases: a mild non-specific conjunctivitis with dry eyes, which improved with warm compresses and artificial tears without any recurrence; and a severe dupilumab-induced follicular conjunctivitis without keratitis, which required specific ophthalmological management.
Collapse
Affiliation(s)
- Adrien Maudinet
- Ophthalmology Department, Lille Catholic Hospitals, Lille Catholic University, Lille, France
| | - Sandrine Law-Koune
- Ophthalmology Department, Lille Catholic Hospitals, Lille Catholic University, Lille, France
| | - Claire Duretz
- Dermatology Department, Lille Catholic Hospitals, Lille Catholic University, Lille, France
| | - Audrey Lasek
- Dermatology Department, Lille Catholic Hospitals, Lille Catholic University, Lille, France
| | - Philippe Modiano
- Dermatology Department, Lille Catholic Hospitals, Lille Catholic University, Lille, France
| | - Thi Ha Chau Tran
- Ophthalmology Department, Saint-Vincent de Paul Hospital, Boulevard de Belfort, Lille Cedex, France.
| |
Collapse
|
21
|
Phan C, Beauchet A, Burztejn A, Severino‐Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj‐Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour J, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse A, Kupfer‐Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles‐Tsimaratos N, Mery‐Brossard L, Pallure V, Lons‐Danic D, Bouilly‐Auvray D, Beylot‐Barry M, Puzenat E, Aubin F, Mahé E. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol 2019; 33:1984-1992. [DOI: 10.1111/jdv.15579] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 02/27/2019] [Indexed: 02/06/2023]
|
22
|
Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, Nosbaum A, Lasek A, Ferrier le Bouedec MC, Du Thanh A, Raison-Peyron N, Tetart F, Duval-Modeste AB, Misery L, Aubin F, Dompmartin A, Morice C, Droitcourt C, Soria A, Arnault JP, Delaunay J, Mahé E, Richard MA, Schoeffler A, Lacour JP, Begon E, Walter-Lepage A, Dillies AS, Rappelle-Duruy S, Barete S, Bellon N, Bénéton N, Valois A, Barbarot S, Sénéchal J, Staumont-Sallé D. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81:143-151. [PMID: 30825533 DOI: 10.1016/j.jaad.2019.02.053] [Citation(s) in RCA: 136] [Impact Index Per Article: 27.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 02/17/2019] [Accepted: 02/22/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. METHODS We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. RESULTS We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10-9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10-9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10-6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. LIMITATIONS No control group, missing data. CONCLUSION This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Collapse
Affiliation(s)
- Sarah Faiz
- CHU de Lille, Service de dermatologie, F-59000 Lille, France
| | - Jonathan Giovannelli
- CHU de Lille, Service de dermatologie, F-59000 Lille, France; Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France
| | - Céline Podevin
- Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France
| | - Marie Jachiet
- Dermatology Department, and Université́ Paris Diderot Paris VII, Sorbonne Paris Cité APHP, Saint Louis Hospital, Paris, France
| | - Jean-David Bouaziz
- Dermatology Department, and Université́ Paris Diderot Paris VII, Sorbonne Paris Cité APHP, Saint Louis Hospital, Paris, France
| | - Ziad Reguiai
- Service de dermatologie, Polyclinique Courlancy, Reims, France
| | - Audrey Nosbaum
- Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, University of Lyon, Lyon, France, CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Audrey Lasek
- Service de dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, France
| | | | - Aurélie Du Thanh
- Service de dermatologie, CHU Montpellier, Univ Montpellier, Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier, France
| | - Nadia Raison-Peyron
- Service de dermatologie, CHU Montpellier, Univ Montpellier, Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier, France
| | - Florence Tetart
- Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France
| | | | - Laurent Misery
- Department of Dermatology, University Hospital of Brest, Brest, France
| | - François Aubin
- Service de dermatologie, Centre Hospitalier Régional Universitaire de Besançon Université de Franche Comté, Besançon, France
| | - Anne Dompmartin
- Department of Dermatology, Caen University Hospital Center, France
| | - Cécile Morice
- Department of Dermatology, Caen University Hospital Center, France
| | - Catherine Droitcourt
- Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France
| | - Angèle Soria
- Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France Sorbonne Universités Paris, Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France
| | | | | | - Emmanuel Mahé
- Department of Dermatology, Hôpital Victor Dupouy Argenteuil, Argenteuil, France
| | - Marie-Aleth Richard
- Aix-Marseille University, EA 3279, CEReSS- Health Service Research and Quality of Life Center, Dermatology Department, Timone Hospital, Assistance Publique Hôpitaux de Marseille, 13385, France
| | - Amélie Schoeffler
- Service de Dermatologie, Hôpital Bel Air, Centre Hospitalier Régional Metz-Thionville
| | | | - Edouard Begon
- Service de Dermatologie, Centre Hospitalier René-Dubos, Pontoise, France
| | | | | | | | - Stéphane Barete
- Unité Fonctionnelle de Dermatologie, Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Paris, France
| | - Nathalia Bellon
- Service de Dermatologie, Hôpital Necker, AP-HP, Paris, France
| | | | - Aude Valois
- Service de Dermatologie, Hôpital d'Instruction des Armées Sainte Anne, Toulon, France
| | | | - Julien Sénéchal
- Service de Dermatologie, Centre de Référence des Maladies Rares de la Peau, Hôpital Saint André, CHU de Bordeaux, France; INSERM U1035 Biothérapie des Maladies Génétiques Inflammatoires et Cancers, Immuno-Dermatologie ATIP AVENIR, Université de Bordeaux, France
| | - Delphine Staumont-Sallé
- CHU de Lille, Service de dermatologie, F-59000 Lille, France; Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France.
| | | |
Collapse
|
23
|
Leblais C, Bataille M, Lasek A, Lebas D, Le Guern A, Modiano P. Sept cas de mucinose érythémateuse réticulée. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
24
|
Maridet C, Perromat M, Miquel J, Chiaverini C, Bessis D, Lasek A, Piram M, Bursztejn AC, Abasq C, Phan A, Martin L, Bréchat B, Chong JH, Seneschal J, Taïeb A, Boralevi F. Childhood chronic prurigo: Interest in patch tests and delayed-reading skin prick tests to environmental allergens. J Allergy Clin Immunol 2018; 141:797-799.e9. [DOI: 10.1016/j.jaci.2017.07.049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Revised: 07/20/2017] [Accepted: 07/31/2017] [Indexed: 11/26/2022]
|
25
|
Lamiaux M, Dabouz F, Wantz M, Lebas D, Lasek A, Courivaud D, Modiano P. Successful combined antibiotic therapy with oral clindamycin and oral rifampicin for pyoderma gangrenosum in patient with PASH syndrome. JAAD Case Rep 2017; 4:17-21. [PMID: 29296643 PMCID: PMC5739174 DOI: 10.1016/j.jdcr.2017.05.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Affiliation(s)
- Marie Lamiaux
- Department of Dermatology, St Vincent de Paul Hospital, Lille, France
| | - Fadia Dabouz
- Department of Dermatology, St Vincent de Paul Hospital, Lille, France
| | - Maud Wantz
- Department of Dermatology, St Vincent de Paul Hospital, Lille, France
| | - Damien Lebas
- Department of Dermatology, St Vincent de Paul Hospital, Lille, France
| | - Audrey Lasek
- Department of Dermatology, St Vincent de Paul Hospital, Lille, France
| | | | - Philippe Modiano
- Department of Dermatology, St Vincent de Paul Hospital, Lille, France.,Lille Catholic University, Lille, France
| |
Collapse
|
26
|
Ahogo KC, Bataille M, Lasek A, Wantz M, Lebas D, Modiano P. [A case of reactive arthritis (oculo-urethro-synovial syndrome) treated with infliximab]. Ann Dermatol Venereol 2017; 144:804-805. [PMID: 28939275 DOI: 10.1016/j.annder.2017.08.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Revised: 05/02/2017] [Accepted: 08/07/2017] [Indexed: 11/25/2022]
Affiliation(s)
- K-C Ahogo
- Service de dermatologie, hôpital Saint-Vincent, université catholique, BP 387, boulevard de Belfort, 59000 Lille, France; CHU Treichville, Abidjan, Cote d'Ivoire.
| | - M Bataille
- Service de dermatologie, hôpital Saint-Vincent, université catholique, BP 387, boulevard de Belfort, 59000 Lille, France
| | - A Lasek
- Service de dermatologie, hôpital Saint-Vincent, université catholique, BP 387, boulevard de Belfort, 59000 Lille, France
| | - M Wantz
- Service de dermatologie, hôpital Saint-Vincent, université catholique, BP 387, boulevard de Belfort, 59000 Lille, France
| | - D Lebas
- Service de dermatologie, hôpital Saint-Vincent, université catholique, BP 387, boulevard de Belfort, 59000 Lille, France
| | - P Modiano
- Service de dermatologie, hôpital Saint-Vincent, université catholique, BP 387, boulevard de Belfort, 59000 Lille, France
| |
Collapse
|
27
|
|
28
|
Modiano P, Wantz M, Durand F, Van Lerberghe L, Lasek A, Lebas D. Intérêt de la photothérapie dynamique dans le syndrome de Rothmund-Thomson. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Gonzales F, Ramdane N, Delebarre-Sauvage C, Modiano P, Duhamel A, Lasek A. Monitoring of topical corticosteroid phobia in a population of parents with children with atopic dermatitis using the TOPICOP®scale: prevalence, risk factors and the impact of therapeutic patient education. J Eur Acad Dermatol Venereol 2016; 31:e172-e174. [DOI: 10.1111/jdv.13961] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- F. Gonzales
- Unité de dermatopédiatrie; Hôpital Saint Vincent de Paul; GHICL Lille; Lille France
| | - N. Ramdane
- Département de Biostatistiques; Université Lille Nord de France; Lille France
| | - C. Delebarre-Sauvage
- Service d'allergologie adultes et enfants; Hôpital Saint Vincent de Paul; GHICL Lille; Lille France
| | - P. Modiano
- Service de dermatologie; Hôpital Saint Vincent de Paul; GHICL Lille; Lille France
| | - A. Duhamel
- Département de Biostatistiques; Université Lille Nord de France; Lille France
| | - A. Lasek
- Service de dermatologie; Hôpital Saint Vincent de Paul; GHICL Lille; Lille France
| |
Collapse
|
30
|
Commin MH, Schmidt E, Duvert-Lehembre S, Lasek A, Morice C, Estival JL, Debarbieux S, Rigal E, Pauwels C, De Quatrebarbes J, Roussel A, Goujon E, Stoebner PE, Jouen F, Joly P. Clinical and immunological features and outcome of anti-p200 pemphigoid. Br J Dermatol 2016; 175:776-81. [DOI: 10.1111/bjd.14629] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/28/2016] [Indexed: 11/30/2022]
Affiliation(s)
- M.-H. Commin
- Department of Dermatology; Rouen University Hospital; Rouen France
- INSERM U 905; Normandy University; Rouen France
| | - E. Schmidt
- Department of Dermatology; University of Lübeck; Lübeck Germany
| | | | - A. Lasek
- Department of Dermatology; Catholic Hospital Group of Lille; Lille France
| | - C. Morice
- Department of Dermatology; Caen University Hospital; Caen France
| | - J.-L. Estival
- Department of Dermatology; Desgenettes Military Hospital; Lyon France
| | - S. Debarbieux
- Department of Dermatology; Lyon-South University Hospital; Lyon France
| | - E. Rigal
- Department of Dermatology; Aurillac General Hospital; Aurillac France
| | - C. Pauwels
- Department of Dermatology; Toulouse University Hospital; Toulouse France
| | | | - A. Roussel
- Department of Dermatology; Orléans Regional Hospital; Orléans France
| | - E. Goujon
- Department of Dermatology; Chalon sur Saône General Hospital; Chalon sur Saône France
| | - P.-E. Stoebner
- Department of Dermatology; Nimes University Hospital; Nimes France
| | - F. Jouen
- INSERM U 905; Normandy University; Rouen France
- Laboratory of Immunology; Rouen University Hospital; Rouen France
| | - P. Joly
- Department of Dermatology; Rouen University Hospital; Rouen France
| |
Collapse
|
31
|
Charbit L, Mahé E, Phan A, Chiaverini C, Boralevi F, Bourrat E, Lasek A, Maruani A, Aubin F, Droitcourt C, Barbarot S, Mallet S, Mazereeuw-Hautier J, Begon E, Abasq C, Plantin P, Souillet AL, Hadj-Rabia S, Bursztejn AC. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol 2016; 174:1118-21. [DOI: 10.1111/bjd.14326] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- L. Charbit
- Department of Dermatology; Centre Hospitalier Universitaire de Nancy; Nancy France
| | - E. Mahé
- Department of Dermatology; Hôpital Victor Dupouy; Argenteuil France
| | - A. Phan
- Pediatric Dermatology Unit; Claude Bernard - Lyon 1 University; Hôpital Femme-Mère-Enfant; Bron France
| | - C. Chiaverini
- Department of Dermatology; Centre Hospitalier Universitaire de Nice Hôpital l'Archet; Nice France
| | - F. Boralevi
- Pediatric Dermatology Unit; Pellegrin Hospital; Bordeaux France
| | - E. Bourrat
- Department of Pediatrics; Assistance Publique Hôpitaux de Paris Hôpital Saint Louis; Paris France
| | - A. Lasek
- Department of Dermatology; Groupe Hospitalier de l'Institut Catholique de Lille; Lille France
| | - A. Maruani
- Department of Dermatology; Centre Hospitalier Régional Universitaire de Tours Hôpital Trousseau et Université François Rabelais Tours; Tours France
| | - F. Aubin
- Department of Dermatology; Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz; Besançon France
| | - C. Droitcourt
- Department of Dermatology; Centre Hospitalier Universitaire de Rennes; Rennes France
| | - S. Barbarot
- Department of Dermatology; Centre Hospitalier Universitaire de Nantes Hôtel-Dieu; Nantes France
| | - S. Mallet
- Department of Dermatology; Assistance Publique Hôpitaux de Marseille Hôpital de la Timone; Marseille France
| | - J. Mazereeuw-Hautier
- Department of Dermatology; Centre Hospitalier Universitaire de Toulouse Hôpital Larrey; Toulouse France
| | - E. Begon
- Department of Dermatology; Centre Hospitalier René Dubos; Pontoise France
| | - C. Abasq
- Department of Dermatology; Centre Hospitalier Régional Universitaire de Brest; Brest France
| | - P. Plantin
- Department of Dermatology; Centre Hospitalier de Cornouaille Hôpital Laënnec; Quimper France
| | - A.-L. Souillet
- Departement of Pneumology-Allergology-Dermatology; Hôpital Femme-Mère-Enfant; Bron France
| | - S. Hadj-Rabia
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC); Department of Dermatology; Université Paris Descartes - Sorbonne Paris Cité; Institut Imagine; Hôpital Universitaire Necker-Enfants Malades; Assistance Publique Hôpitaux de Paris; Paris France
| | - A.-C. Bursztejn
- Department of Dermatology; Centre Hospitalier Universitaire de Nancy; Nancy France
| | | |
Collapse
|
32
|
Moawad S, Aubert H, Phan A, Maruani-Raphael A, Chiaverini C, Bodemer C, Mazereeuw-Hautier J, Lasek A, Droitcourt C, Barbarot S, Mahé E, Bursztein AC. Évaluation de la corticophobie chez les enfants atteints de psoriasis versus dermatite atopique : étude multicentrique nationale chez 122 enfants. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Gonzales F, Lasek A. CO-57 – Corticophobie en dermato-pédiatrie et impact de 'éducation thérapeutique. Arch Pediatr 2015. [DOI: 10.1016/s0929-693x(15)30157-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
34
|
Bataille M, Colmant C, Spanoudi I, Wantz M, Lasek A, Godart C, Modiano P. Quand le dermatologue complète avec succès le rhumatologue. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
35
|
Guedes De Carvalho D, Spanoudi-Kitrimi I, Wantz M, Lasek A, Modiano P. Pemphigus herpétiforme traité efficacement par dapsone. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.425] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Charbit L, Mahe E, Phan A, Droitcourt C, Boralevi F, Puzenat E, Abasq C, Aubert H, Barbarot S, Avenel-Audran M, Rodriguez L, Begon E, Mallet S, Balguerie X, Aubin F, Piram M, Souillet AL, Maruani A, Plantin P, Bourrat E, Lacour JP, Chiaverini C, Mazereeuw-Hautier J, Labreze C, Lasek A, Fleuret C, Kupfer I, Hadj-Rabia S, Bursztejn AC. Traitements systémiques du psoriasis de l’enfant : étude multicentrique nationale chez 140 enfants. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
37
|
Boralevi F, Cadet L, Ezzedine K, Bourrat E, Raison N, Eschard C, Sarre ME, Giordano-Labadie F, Phan A, Souillet AL, Aubert H, Lasek A, Bernier C, Léauté-Labrèze C, Milpied B. Facteurs favorisants des granulomes post-vaccinaux liés à l’aluminium : une enquête multicentrique cas-témoins. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
|
39
|
Ahogo KC, Menet V, Modiano P, Lasek A. Crises de pleurs inconsolables révélatrices d’une érythermalgie primitive chez un nourrisson de 6 mois. Arch Pediatr 2014; 21:299-301. [DOI: 10.1016/j.arcped.2013.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2013] [Revised: 08/07/2013] [Accepted: 12/09/2013] [Indexed: 10/25/2022]
|
40
|
Wantz M, Spanoudi-Kitrimi I, Lasek A, Lebas D, Quinchon JF, Modiano P. [Vemurafenib-induced toxic epidermal necrolysis]. Ann Dermatol Venereol 2013; 141:215-8. [PMID: 24635957 DOI: 10.1016/j.annder.2013.10.054] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2013] [Revised: 09/09/2013] [Accepted: 10/29/2013] [Indexed: 11/24/2022]
Abstract
BACKGROUND Herein we report the first case of toxic epidermal necrolysis (TEN) occurring with use of vemurafenib. PATIENTS AND METHODS A 75-year-old female patient was being treated with vemurafenib for stage IV melanoma with BRAF V600E mutation. She suddenly presented fever, diffuse pruriginous maculopapular erythema, palpebral edema, palmar bulla, conjunctivitis, cheilitis and mucosal ulceration. The condition progressed towards detachment affecting 50% of the skin area. Cutaneous biopsy revealed lichenoid dermatosis, chiefly vesicular with numerous eosinophils. Direct immunofluorescence (IFD) was negative. Vemurafenib was the only drug to which the reaction was ascribable and we concluded on vemurafenib-induced TEN. DISCUSSION To our knowledge, this is the first reported case of vemurafenib-induced TEN, but this adverse effect, although already described in the BRIM-3 study, appears rare in clinical practice. Other severe skin reactions have been described in the literature. These include a case of Stevens-Johnson syndrome in a female patient treated with vemurafenib and previously receiving ipilimumab. A more common occurrence is cutaneous reactions involving efflorescence of benign hyperkeratotic lesions, occasionally accompanied by authentic epidermal carcinoma or keratoacanthoma, and requiring regular dermatological monitoring of patients treated with vemurafenib. CONCLUSION If maculopapular exanthema occurs under vemurafenib, continuation of this treatment should be reassessed since the risk of progression to a more serious condition such as TEN, as seen in the present case, cannot be ruled out.
Collapse
Affiliation(s)
- M Wantz
- Service de dermatologie, hôpital Saint-Vincent-de-Paul, GHICL, boulevard de Belfort, 59000 Lille, France.
| | - I Spanoudi-Kitrimi
- Service de dermatologie, hôpital Saint-Vincent-de-Paul, GHICL, boulevard de Belfort, 59000 Lille, France
| | - A Lasek
- Service de dermatologie, hôpital Saint-Vincent-de-Paul, GHICL, boulevard de Belfort, 59000 Lille, France
| | - D Lebas
- Service de dermatologie, hôpital Saint-Vincent-de-Paul, GHICL, boulevard de Belfort, 59000 Lille, France
| | - J-F Quinchon
- Service d'anatomopathologie, hôpital Saint-Vincent-de-Paul, GHICL, boulevard de Belfort, 59000 Lille, France
| | - P Modiano
- Service de dermatologie, hôpital Saint-Vincent-de-Paul, GHICL, boulevard de Belfort, 59000 Lille, France
| |
Collapse
|
41
|
Wantz M, Lasek A, Spanoudi-Kitrimi I, Lebas D, Modiano P. Syndrome de larva migrans cutanée acquis à Lille, nord de la France. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.508] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Wantz M, Spanoudi-Kitrimi I, Lasek A, Lebas D, Modiano P. Nécrolyse épidermique toxique au vemurafenib, à propos d’un cas. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Lasek A, Lebas D, Modiano P. Hypomélanose maculeuse progressive de l’adolescent. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
44
|
Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 2013; 168:555-62. [PMID: 23136927 DOI: 10.1111/bjd.12125] [Citation(s) in RCA: 245] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND Drug patch tests (PTs) can reproduce delayed hypersensitivity to drugs and entail a moderate re-exposure of patients to offending drugs. OBJECTIVES To determine the value of PTs for identifying the responsible drug in severe cutaneous adverse drug reactions (SCARs) such as acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). METHODS In a multicentre study, PTs were conducted on patients referred for DRESS, AGEP or SJS/TEN within 1 year of their SCAR. All drugs administered in the 2 months prior to and the week following the onset of the SCAR were tested. RESULTS Among the 134 patients included (48 male, 86 female; mean age 51·7 years), positive drug PTs were obtained for 24 different drugs. These included positive tests for 64% (46/72) of patients with DRESS, 58% (26/45) of those with AGEP and 24% (4/17) of those with SJS/TEN, with only one relapse of AGEP. The value of PTs depended on the type of drug and the type of SCAR (e.g. carbamazepine was positive in 11/13 DRESS cases but none of the five SJS/TEN cases). PTs were frequently positive for beta lactams (22 cases), pristinamycin (11 cases) and in DRESS with pump proton inhibitors (five cases), but were usually negative for allopurinol and salazopyrin. Of 18 patients with DRESS, eight had virus reactivation and positive PTs. In DRESS, multiple drug reactivity was frequent (18% of cases), with patients remaining sensitized many years later. CONCLUSIONS PTs are useful and safe for identifying agents inducing SCAR.
Collapse
Affiliation(s)
- A Barbaud
- Dermatology Department, University Hospital of Nancy, Pôle des Spécialités Médicales, Université de Lorraine, Brabois Hospital, 6 Rue du Morvan, Vandoeuvre-lès-Nancy 54500, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Lasek A, Danigo A, Beudin C, Castelain MC, Modiano P. Évaluation d’un programme d’éducation thérapeutique de la dermatite atopique chez 152 enfants. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
46
|
Lasek A, Castelain M, Modiano P. Eczéma de contact aigu au méthoxy PEG-22 dodécyl glycol contenu dans le Mustela Cold Cream® nutriprotecteur. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Van Lerberghe L, Lasek A, Wantz M, Gosset P, Jouen F, Modiano P. Pemphigoïde anti-p200. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Lasek A, Menet V, Modiano P. Crises de pleurs inconsolables du nourrisson associées à un érythème des membres inférieurs. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Lasek A, Besset S, Gros C, Modiano P. Syndrome de Wells de l’enfant. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Duparc A, Lasek A, Gros C, Delaporte E, Van der Linden T, Modiano P. Nécrolyse épidermique toxique à la lamotrigine par erreur de délivrance. Ann Dermatol Venereol 2010; 137:736-8. [DOI: 10.1016/j.annder.2010.06.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2010] [Revised: 06/02/2010] [Accepted: 06/29/2010] [Indexed: 10/19/2022]
|